In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …

Although surgery was the mainstay of treatment for valvular heart disease, transcatheter
valve therapies have grown exponentially over the past decade. Two types of artificial heart …

Background Frailty is a geriatric syndrome that diminishes the potential for functional
recovery after a transcatheter aortic valve replacement (TAVR) or surgical aortic valve …

Objectives: The aim of this study was to compare aspirin plus clopidogrel with aspirin alone
as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare …

Bioprosthetic valve (BPV) thrombosis is considered a relatively rare clinical entity. Yet a
more recent analysis involving a more systematic echocardiographic follow-up, the advent of …

Background Antithrombotic treatment regimen following transcatheter aortic valve
replacement (TAVR) is not evidence-based. Apixaban, a non-vitamin K direct anticoagulant …

Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with
valvular heart disease (VHD) is also common. However, management strategies for this …

Transcatheter aortic valve implantation (TAVI) or replacement has rapidly changed the
treatment of patients with severe symptomatic aortic stenosis. It is now the standard of care …

Objectives: The study sought to examine the risk of ischemic events and bleeding episodes
associated with differing antithrombotic strategies in patients undergoing transcatheter aortic …